Coya Therapeutics (NASDAQ:COYA) Upgraded by Roth Mkm to “Strong-Buy” Rating

Posted by Brian Himes on Jun 6th, 2026

Coya Therapeutics (NASDAQ:COYA – Get Free Report) was upgraded by investment analysts at Roth Mkm to a “strong-buy” rating in a report released on Friday,Zacks.com reports.

Other research analysts have also recently issued reports about the company. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research report on Monday, March 16th. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research note on Monday, March 23rd. D. Boral Capital reissued a “buy” rating and set a $15.00 target price on shares of Coya Therapeutics in a research note on Friday, April 10th. Wall Street Zen downgraded Coya Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $15.33.

Read Our Latest Report on Coya Therapeutics

Coya Therapeutics Price Performance

Shares of NASDAQ:COYA opened at $4.42 on Friday. Coya Therapeutics has a 1-year low of $3.71 and a 1-year high of $7.75. The business has a fifty day moving average price of $4.45 and a 200-day moving average price of $4.90. The company has a market capitalization of $103.69 million, a PE ratio of -3.84 and a beta of 0.62.

Coya Therapeutics (NASDAQ:COYA – Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.07. Coya Therapeutics had a negative return on equity of 55.86% and a negative net margin of 266.10%.The company had revenue of $0.25 million during the quarter, compared to the consensus estimate of $0.15 million. On average, sell-side analysts anticipate that Coya Therapeutics will post -1.5 earnings per share for the current fiscal year.

Institutional Trading of Coya Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cetera Investment Advisers bought a new stake in Coya Therapeutics during the 4th quarter valued at approximately $128,000. Millennium Management LLC bought a new stake in Coya Therapeutics during the 4th quarter valued at approximately $121,000. Northwestern Mutual Wealth Management Co. bought a new stake in Coya Therapeutics in the 2nd quarter worth approximately $119,000. Occudo Quantitative Strategies LP bought a new stake in Coya Therapeutics in the 4th quarter worth approximately $66,000. Finally, CIBC Private Wealth Group LLC bought a new stake in Coya Therapeutics in the 4th quarter worth approximately $47,000. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

(Get Free Report)

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.